FOR LABORATORY RESEARCH USE ONLY · NOT FOR HUMAN CONSUMPTION
GHRP-6PEPPUDEX

GHRP-6 · SUBTOPIC · SAFETY PROFILE

GHRP-6 Safety Profile

For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of GHRP-6.

OBSERVED ADVERSE EVENTS IN LITERATURE

The following adverse events have been observed in trials or animal studies of GHRP-6. Severity, frequency, and attribution depend on the source publication.

  • Strong appetite stimulation
  • Mild cortisol elevation
  • Mild prolactin elevation
  • Flushing
  • Injection-site reactions

DRUG INTERACTIONS

The following interactions are reported in or theorised from the published mechanism for GHRP-6.

  • Concurrent rhGH not recommended
  • Glucocorticoids may blunt response

CONTRAINDICATIONS REPORTED IN LITERATURE

Contraindications recorded for GHRP-6 in the published record:

  • Active malignancy
  • Pituitary tumor
  • Pregnancy/lactation

FDA REGULATORY STATUS

Not FDA-approved. Research-use only.

WADA REGULATORY STATUS

Prohibited at all times under WADA Section S2 (growth-hormone-secretagogue sub-category).

SAFETY Q+A FROM LITERATURE

Is GHRP-6 FDA-approved?

No. Research-use only.

Is GHRP-6 WADA-prohibited?

Yes. GHRP-6 is prohibited at all times under WADA Section S2 in the growth-hormone-secretagogue sub-category.

How is GHRP-6 paired with a GHRH analog?

GHRP-6 + CJC-1295 No DAC engages both upstream regulators of GH release. The two pathways are independent and complementary; combined activation amplifies the GH pulse synergistically. Less commonly used than ipamorelin + CJC-1295 due to GHRP-6's appetite and stress-hormone side effects.

CITED LITERATURE

The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.

  • Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984. link
  • Smith RG, Van der Ploeg LH, Howard AD, et al.. Peptidomimetic regulation of growth hormone secretion. Endocr Rev 1997. link

RELATED PAGES

GHRP-6 OVERVIEWMECHANISM ▶DOSING LITERATURE ▶

▶ LAST UPDATED · 2026-05-25

© 2026 Peppu Studio LLC · For Laboratory Research Use Only